We next tested a range of CBN concentrations to determine what concentration of CBN was required to trigger a positive immunoassay result. Methods: Deidentified residual patient urine samples that tested negative for THC metabolite on initial testing were pooled and fortified with the above compounds to detect cross-reactivity. The objective of this study was to assess the cross-reactivity of 2 commercial immunoassays designed to detect THC metabolite with 4 cannabinoids: cannabidiol, cannabinol, cannabichromene, and cannabigerol. This is especially important as cannabinoid products are increasingly marketed as legal supplements. Since cannabinoids have extensive structural similarity, it is important to be aware of potential cross-reactivity with immunoassays designed to detect THC metabolite.
However, the length of time following drug use for which a positive result may occur is dependent upon several factors, including the frequency and amount of drug, metabolic rate, excretion rate, drug half-life, and the drug user's age, weight, activity, and diet.īackground: The psychoactive component of cannabis, tetrahydrocannabinol (THC), is one of many cannabinoids present in the plant. The main metabolite excreted in the urine is 11-nor-Δ9-THC-9-COOH, which are found within hours of exposure and remain detectable in the urine for 3-10 days after smoking. Δ9-THC is the primary active ingredient in cannabinoids.
A tolerance to the cardiac and psychotropic effects can occur and withdrawal syndrome produces restlessness, insomnia, anorexia and nausea. Large doses of cannabinoid could cause the development of tolerances and physiological dependency and lead to abuse.
Cannabinoid is a central nervous stimulant that alters mood and sensory perceptions, produces loss of coordination, impairs short term memory, produces symptoms of anxiety, paranoia, depression, confusion, hallucination, and increased heart rate. The agents of Marijuana that cause various biological effects in humans are called cannabinoid.
0 kommentar(er)
